| Field | Specification |
|---|---|
| Target | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H20ClFN2OS |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Multi-kinase-IN-4 is a multi-targeted kinase inhibitor acting on VEGFR2, EGFR, HER2 and CDK2, with IC50 values of 0.33 μM, 0.22 μM, 0.18 μM and 2.09 μM, respectively. It shows broad-spectrum anticancer activity against HepG2, MCF-7, MDA-231 and HeLa cells (IC50 1.94–7.1 μM) while being less toxic to WI-38 cells (IC50 40.85 μM), and it induces apoptosis and S-phase cell cycle arrest in HepG2 cells, giving it potential for cancer research[1]. It has the molecular formula C21H20ClFN2OS and a molecular weight of 402.91 g/mol.
Physical & Chemical Properties
| Molecular Formula | C21H20ClFN2OS |
|---|---|
| Molecular Weight | 402.91 g/mol |
| SMILES | O=C1N(C/C=C(CC)\C)C(SCC2=CC=C(Cl)C=C2)=NC3=C1C=C(F)C=C3 |
| Target | VEGFR2, CDK2, HER2 |
| Signaling Pathway | Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage; JAK/STAT Signaling; Apoptosis |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
|
VEGFR2 0.33 μM (IC50) |
CDK2 2.09 μM (IC50) |
HER2 0.18 mM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
Multi-kinase-IN-4 (48 h) is cytotoxic to HepG2, MCF-7, MDA-231, and HeLa cells, with IC50 values of 7.10, 2.48, 1.94, and 6.38 μM, respectively, whereas its cytotoxic activity against WI38 cells is lower (IC50 = 64.29 μM) [1]. In HepG2 cells, Multi-kinase-IN-4 (7.1 μM, 24 h) raises the cell population in S phase by 9.23% and lowers it in G0-G1 and G2/M phases by 4.50% and 4.73%, respectively[1]. In HepG2 cells, Multi-kinase-IN-4 (7.1 μM, 24 h) triggers early apoptosis, late apoptosis, and necrotic cell death at 7.51%, 3.45%, and 3.08%, respectively[1].
Apoptosis Analysis[1]
| Cell Line | HepG2 |
|---|---|
| Concentration | 7.1 μM |
| Incubation Time | 24h |
| Result | Induced early and late apoptosis as well as necrotic cell death by 7.51%, 3.45%, and 3.08%, respectively. |
Cell Cycle Analysis[1]
| Cell Line | HepG2 |
|---|---|
| Concentration | 7.1 μM |
| Incubation Time | 24h |
| Result | Increased the cell population of 9.23% at the S phase and results in a drop in the cell population at the G0-G1 and G2/M phases: 4.50% and 4.73%, respectively |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
